- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Collegium Pharmaceutical Inc (COLL)
Collegium Pharmaceutical Inc stock price live, this page displays NASDAQ COLL stock exchange data. View the COLL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Collegium Pharmaceutical Inc real time stock price chart below.
What Is the Collegium Pharmaceutical Inc Stock Price Today?
The Collegium Pharmaceutical Inc stock price today is 29.56.
What Is the Stock Symbol for Collegium Pharmaceutical Inc?
The stock symbol for Collegium Pharmaceutical Inc is "COLL."
What Stock Exchange Does Collegium Pharmaceutical Inc Trade On?
Collegium Pharmaceutical Inc is listed and trades on the NASDAQ stock exchange.
Is Collegium Pharmaceutical Inc a Good Stock to Buy?
Determining whether Collegium Pharmaceutical Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the COLL quote. (ISIN: US19459J1043)
What Is the Collegium Pharmaceutical Inc Stock Price Today?
The Collegium Pharmaceutical Inc stock price today is 29.56.
What Is the Stock Symbol for Collegium Pharmaceutical Inc?
The stock symbol for Collegium Pharmaceutical Inc is "COLL."
What Stock Exchange Does Collegium Pharmaceutical Inc Trade On?
Collegium Pharmaceutical Inc is listed and trades on the NASDAQ stock exchange.
Is Collegium Pharmaceutical Inc a Good Stock to Buy?
Determining whether Collegium Pharmaceutical Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the COLL quote. (ISIN: US19459J1043)
NASDAQ
Currency in USD
29.56
+0.67(+2.32%)
Closed·
Pre Market
29.89+0.33(+1.12%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
29.53
30.46
52 wk Range
23.23
42.29
COLL Scorecard
Full Analysis
Management has been aggressively buying back shares
COLL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
29.5330.46
52 wk Range
23.2342.29
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
COLL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
43.00
Upside
+45.47%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Collegium Pharmaceutical Inc Company Profile
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Collegium Pharmaceutical Inc Earnings Call Summary for Q1/2025
- Net product revenues reached $177.8M, up 23% YoY; stock rose 0.85% to $27.27 in aftermarket trading
- Jornay PM (ADHD medication) saw 24% prescription growth; BELBUCA revenue up 2% YoY to $51.7M
- Cash position improved by $35M to $197.8M; Non-GAAP adjusted EBITDA up 3% YoY to $95.2M
- 2025 guidance: net product revenues $735M-$750M (18% increase); Jornay PM expected to exceed $135M
- CEO emphasized leadership in responsible pain management; plans to reduce operating expenses in H2 2025
Last Updated: 09/05/2025, 07:16 am
Read Full TranscriptCompare COLL to Peers and Sector
Metrics to compare | COLL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCOLLPeersSector | |
|---|---|---|---|---|
P/E Ratio | 21.6x | −1.1x | −0.5x | |
PEG Ratio | −0.47 | 0.00 | 0.00 | |
Price/Book | 4.1x | 0.7x | 2.6x | |
Price / LTM Sales | 1.4x | 2.0x | 2.9x | |
Upside (Analyst Target) | 42.1% | 56.9% | 53.0% | |
Fair Value Upside | Unlock | 22.8% | 8.9% | Unlock |
Analyst Ratings
4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 43.00
(+45.47% Upside)
Earnings
Latest Release
May 08, 2025
EPS / Forecast
1.49 / 1.50
Revenue / Forecast
177.76M / 174.04M
People Also Watch
FAQ
What Is the Collegium Pharmaceutical (COLL) Stock Price Today?
The Collegium Pharmaceutical stock price today is 29.56
What Stock Exchange Does Collegium Pharmaceutical Trade On?
Collegium Pharmaceutical is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Collegium Pharmaceutical?
The stock symbol for Collegium Pharmaceutical is "COLL."
What Is the Collegium Pharmaceutical Market Cap?
As of today, Collegium Pharmaceutical market cap is 950.12M.
What Is Collegium Pharmaceutical's Earnings Per Share (TTM)?
The Collegium Pharmaceutical EPS (TTM) is 1.37.
When Is the Next Collegium Pharmaceutical Earnings Date?
Collegium Pharmaceutical will release its next earnings report on 30 July 2025.
From a Technical Analysis Perspective, Is COLL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.